At present, research on predictive markers of immunotherapy mainly focuses on positive predictors of efficacy, such as programmed death-ligand 1 (PD-L1), tumor mutational burden (TMB), microsatellite high instability (MSI-H) and mismatch repair deficiency (dMMR). The gene discussed is CD274; the disease is hyperinsulinemic hypoglycemia, familial, 4.